112 related articles for article (PubMed ID: 26104896)
1. [Role of RRM1 in the Treatment and Prognosis of Advanced Non-small Cell Lung Cancer].
Tian J; Han S
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):381-6. PubMed ID: 26104896
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis.
Zhu CM; Lian XY; Bi YH; Hu CC; Liang YW; Li QS
Clin Chim Acta; 2018 Oct; 485():67-73. PubMed ID: 29803896
[TBL] [Abstract][Full Text] [Related]
3. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer.
Feng JF; Wu JZ; Hu SN; Gao CM; Shi MQ; Lu ZH; Sun XC; Zhou JR; Chen BA
Lung Cancer; 2009 Dec; 66(3):344-9. PubMed ID: 19304340
[TBL] [Abstract][Full Text] [Related]
5. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
Lee JJ; Maeng CH; Baek SK; Kim GY; Yoo JH; Choi CW; Kim YH; Kwak YT; Kim DH; Lee YK; Kim JB; Kim SY
Lung Cancer; 2010 Nov; 70(2):205-10. PubMed ID: 20223551
[TBL] [Abstract][Full Text] [Related]
6. RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report.
Zeng C; Fan W; Zhang X
Cell Oncol (Dordr); 2015 Aug; 38(4):319-25. PubMed ID: 26092210
[TBL] [Abstract][Full Text] [Related]
7. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
Xu XL; Zhang YP; Fang Y; Su D; Chen W; Feng JG; Li ZP; Mao WM
J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C49-55. PubMed ID: 26323924
[TBL] [Abstract][Full Text] [Related]
8. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of ERCC1, RRM1 and TS in non-small cell lung cancer].
Li P; Kang X; Chen K
Zhongguo Fei Ai Za Zhi; 2014 Jun; 17(6):496-500. PubMed ID: 24949692
[No Abstract] [Full Text] [Related]
11. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
Simon G; Sharma A; Li X; Hazelton T; Walsh F; Williams C; Chiappori A; Haura E; Tanvetyanon T; Antonia S; Cantor A; Bepler G
J Clin Oncol; 2007 Jul; 25(19):2741-6. PubMed ID: 17602079
[TBL] [Abstract][Full Text] [Related]
12. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
[TBL] [Abstract][Full Text] [Related]
13. Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancer.
Jakobsen JN; Santoni-Rugiu E; Sørensen JB
Histopathology; 2014 Feb; 64(3):412-20. PubMed ID: 24266856
[TBL] [Abstract][Full Text] [Related]
14. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.
Mohammed Ael S; Eguchi H; Wada S; Koyama N; Shimizu M; Otani K; Ohtaki M; Tanimoto K; Hiyama K; Gaber MS; Nishiyama M
Exp Lung Res; 2012 Nov; 38(9-10):463-74. PubMed ID: 23098063
[TBL] [Abstract][Full Text] [Related]
15. [Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)].
Danzinger S; Filipits M
Wien Med Wochenschr; 2007; 157(21-22):554-61. PubMed ID: 18157593
[TBL] [Abstract][Full Text] [Related]
16. [Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer].
Zhang S; Liu J; Cheng Y
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):232-9. PubMed ID: 25936888
[TBL] [Abstract][Full Text] [Related]
17. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
18. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer.
Han Y; Wang XB; Xiao N; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(5):2987-90. PubMed ID: 23803067
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy after pulmonary resection for lung cancer.
Mascaux C; Shepherd FA
Thorac Surg Clin; 2013 Aug; 23(3):401-10. PubMed ID: 23931022
[TBL] [Abstract][Full Text] [Related]
20. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.
Vilmar A; Garcia-Foncillas J; Huarriz M; Santoni-Rugiu E; Sorensen JB
Lung Cancer; 2012 Mar; 75(3):306-12. PubMed ID: 21996087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
